Hamza Hashmi
@hhashmi87
Followers
756
Following
810
Media
132
Statuses
474
Myeloma & Cellular Therapy physician at @MSKCancerCenter #MMSM #ASTCT #CART Opinions are my own
New York, USA
Joined May 2018
About 30% of the #MMSM pts had to stop reading/driving 3 mo into treatment and almost everyone was able to resume these activities within a mo with only one such occurrence likely due to dose modification. This is very detailed and helpful data for QOL and informed consent.
Great @BloodAdvances paper by @mvmateos @thanosdimop et al: pooled data for dose mods from DREAMM-7 & -8. With bela-maf in #MMsm, dose de-escalations are not the exception. they are the norm! . Over 70% of pts with responses had ≥3 separate dose interruptions in both trials.
1
2
14
Great day sharing ideas, research, and debates on #myeloma with @bhemato and colleagues at MMSparks event in @merida #CureMyeloma #mmsm #MedEd #medtwitter #CART #bispecifics #MyelomaMexico #MyelomaFriends
2
2
19
Generate videos in just a few seconds. Try Grok Imagine, free for a limited time.
696
3K
9K
Wonderful opportunity sharing #BestofASCO 2025 highlights in Multiple Myeloma. How to (and not to) apply recent trial data in clinical practice. Some great talks on Leukemia, Lymphoma. #MMSM #CART #ASCODirect #ASCO25 #MedTwitter #MedEd @TotalHealthConf @ASCO .@MSKCancerCenter
0
8
25
ASCO® 2025 Summary: Best of Myeloma-Key Trials & Clinical Insights | VuMedi @vumedi.➡️Highlights, Summary, Take Home Messages.➡️Practice Changing vs Practice Informing.@ASCO @oncodaily @MM_Hub @MSKCancerCente @ASHClinicalNews #MedTwitter #MedEd #ASCO25
1
3
8
RT @NausheenAhmedMD: This is a major win for patients . we have been advocating this with our publications on access ! Finally - REMS is re….
0
5
0
RT @mdbrunocosta: Proud to see our work finally out in #BloodICT @BloodPortfolio—thank you for the mentorship! It's been an incredible jour….
0
4
0
Proud of this detailed #Talquetamab #Toxicity work by our resident @mdbrunocosta 👏🙏🙌.@szusmani @CarlynRTanMD @MSKCancerCenter .@ASH_hematology @ASHClinicalNews @oncodaily .@MM_Hub #MMSM #MedTwitter #MedEd #LessIsMore.
0
0
3
➡️n=51, 94% TCR, 71% w prior TCE.➡️Weight loss 70%, altered taste 70% & Nail changes in 50% pts.⬇️frequency⬇️intensity &🛑Rx in 18%, 10%, and 8% pts.➡️Nearly 50% w Rx modification had an ongoing response with ⬆️recovery from weight loss (64% vs 41%) & taste changes (38% vs 23%).
1
0
2
Hot off press: Practical Use of Talquetamab in Relapsed/Refractory Multiple Myeloma: The MSKCC Experience in #BloodImmunologyAndCellTherapy .
1
0
8
#ComedyVsCancer @LincolnCenter in #NYC. Thank you @MSKCancerCenter for getting me the tix for this comedy event!! #ILoveComedy #Comedy #cancer #LetsCureCancer #LetsDoComedy #MMSM
0
1
3
RT @RahulBanerjeeMD: 🤣 Good for @Myeloma_Society for bringing out the puns already!. Excited for #IMS25 🇨🇦 . Cc @szusmani @Mohty_EBMT @Josh….
0
7
0
RT @oncodaily: Myeloma Paper of the Day, May 3rd, suggested by Robert Orlowski (@Myeloma_Doc).@MDAndersonNews @szusmani. .
0
2
0
Proud of this work by our 3rd yr medical resident Benjamin Adegbite 🙌👏🙏.@szusmani @CarlynRTanMD @MSKCancerCenter @BloodAdvances @ASH_hematology @ASHClinicalNews @MM_Hub #MMSM #MedTwitter #FrailtyNoBarrier.
0
0
1
➡️N=101 (all BCMA BsAb), 40% frail by SFI = Age + CCI + ECOG).➡️ORR (80% VS 73%), PFS (NR vs 11m), OS (35 vs 24m).➡️CRS (58% vs 60%), ICANS (15% vs 8%), TRM (13% vs 21%). 💡BsAb are safe + effective in frail & elderly pts with #RRMM.💡⬆️Age,⬇️ ECOG,⬆️comorbidities ≠⬇️⬇️outcomes.
1
0
2
Hot off Press: 'Outcomes in Frail Patients Receiving BCMA-directed Bispecific Antibodies for Relapsed/Refractory Multiple Myeloma' in @BloodAdvances
1
7
18
RT @JoshuaRichterMD: Are you ready for controversies in myeloma? Getting excited to discuss what happens beyond immunotherapy with @Dott….
0
9
0
RT @sridevirajeeve: Looking forward to the inaugural #iwGPRC5D International Workshop on GPRC5D-Targeted Myeloma Therapies on March 22 in N….
0
6
0
RT @myelomadoctor: Can a signature be developed to predict relapse post CAR-T in multiple myeloma patients? Important question to be answer….
0
3
0
Great job by @ABidikianMD presenting his first proposal at the @CIBMTR working committee meeting. Many more to come.
1
0
7